Nuformix plc (NFX.L) LSE
0.18
+0(+0.00%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
0.18
+0(+0.00%)
Currency In GBp
Address
60 Gracechurch Street
London, EC3V 0HR
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1223 627222
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3
First IPO Date
December 17, 2015
| Name | Title | Pay | Year Born |
| Daniel John Gooding | Executive Director | 30,000 | 1973 |
| Joanne Holland | Consultant | 0 | 1975 |
| Shaun Zulafqar | Company Secretary | 0 | N/A |
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.